Bjerkenstedt L, Härnryd C, Grimm V, Gullberg B, Sedvall G
Arch Psychiatr Nervenkr (1970). 1978 Dec 14;226(3):157-72. doi: 10.1007/BF00341708.
Eighty-one women with psychosis of schizophrenic and paranoid type were assigned to a double-blind study comparing the clinical effects of melperone (100 mg X 3) and thiothixene (10 mg X 3). The antipsychotic effect was evaluated by clinical rating according to the CPRS and the NOSIE-30 scales before and after 2 and 4 weeks of drug treatment. A satisfactory interrater reliability was obtained for the CPRS. Significant correlation was also found between the CPRS and NOSIE ratings. Treatment with both drugs was associated with significant reductions in morbidity as estimated by several measures of therapeutic effect from the CPRS, by the NOSIE scale and by global ratings. There were no marked differences at any rating time point between the drugs in this regard. There were more extrapyramidal side effects in the thiothixene group than in the melperone-treated patients. The results encourage the use and further evaluation of melpherone in the treatment of psychotic patients.
81名患有精神分裂症和偏执型精神病的女性被分配到一项双盲研究中,比较了美哌隆(100毫克×3)和硫利达嗪(10毫克×3)的临床效果。在药物治疗2周和4周前后,根据CPRS和NOSIE - 30量表通过临床评分评估抗精神病效果。CPRS获得了令人满意的评分者间信度。CPRS和NOSIE评分之间也发现了显著相关性。根据CPRS的几种治疗效果测量方法、NOSIE量表和整体评分估计,两种药物治疗均与发病率显著降低相关。在这方面,两种药物在任何评分时间点均无明显差异。硫利达嗪组的锥体外系副作用比美哌隆治疗的患者更多。结果鼓励在精神病患者治疗中使用美哌隆并对其进行进一步评估。